Fatty acids in context

Neurometabolic perspectives on depression vulnerability

Mocking, R.J.T.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)

Download date: 04 Dec 2019
DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?

ABSTRACT

**Background:** Major depressive disorder (MDD) has been associated with low dehydroepiandrosterone-sulphate (DHEAS), - particularly relative to high cortisol - although conflicting findings exist. Moreover, it is unclear whether low DHEAS is only present during the depressive state, or manifests as a trait that may reflect vulnerability for recurrence. Therefore, we longitudinally tested whether low DHEAS and high cortisol/DHEAS-ratio in recurrent MDD (I) reflects a trait, and/or (II) varies with depressive state. In addition, we tested associations with (III) previous MDD-episodes, (IV) prospective recurrence, and (V) effects of cognitive therapy.

**Methods:** At study-entry, we cross-sectionally compared morning and evening salivary DHEAS and molar cortisol/DHEAS-ratio of 187 remitted recurrent MDD-patients with 72 matched controls. Subsequently, patients participated in an 8-week randomized controlled cognitive therapy trial. We repeated salivary measures after 3 months and 2 years. We measured clinical symptoms during a 10-year follow-up.

**Results:** Remitted patients showed steeper diurnal DHEAS-decline ($P < .005$) and a flatter diurnal profile of cortisol/DHEAS-ratio ($P < .001$) than controls. We found no state-effect in DHEAS or cortisol/DHEAS-ratio throughout follow-up and no association with number of previous episodes. Higher morning cortisol/DHEAS-ratio predicted shorter time till recurrence over the 10-year follow-up in interaction with the effects of cognitive therapy ($P < .05$). Finally, cognitive therapy did not influence DHEAS or cortisol/DHEAS-ratio.

**Conclusions:** Diurnal profiles of DHEAS and cortisol/DHEAS-ratio remain equally altered in between depressive episodes, and may predict future recurrence. This suggests they represent an endophenotypic vulnerability trait rather than a state-effect, which provides a new road to understand recurrent depression and its prevention.

**Trial registration:** www.isrctn.com/ISRCTN68246470.
INTRODUCTION

Major depressive disorder (MDD) represents a large burden of disease, mainly due to its high recurrence and cardiovascular comorbidity risks.\(^{26,68}\) Indicatively, 80% of recovered MDD-patients experience an average of five recurrences during lifetime,\(^{19}\) and cardiovascular disease is a leading cause of death in MDD.\(^{66}\) If we better understand recurrent MDD’s pathophysiology, we may improve prevention of recurrence and cardiovascular disease in at-risk patients.

An important pathophysiological characteristic of MDD is altered activity of the hypothalamic-pituitary-adrenal (HPA)-axis.\(^{11}\) HPA-axis hormone cortisol has been extensively studied, and mainly found to be present in higher concentrations in MDD-patients,\(^{11}\) which was also reported by our group in the present study’s sample of patients with recurrent MDD.\(^{69}\) The potentially detrimental effects of chronic high cortisol has been termed allostatic load,\(^6\) which may explain e.g. reduced hippocampal volumes and atherosclerosis, contributing to the extensive recurrence and cardiovascular comorbidity rates in MDD.

However, more abundantly than cortisol, adrenal glands also secrete the neuroactive steroids dehydroepiandrosterone (DHEA) and its sulfate ester DHEAS [jointly referred to as DHEA(S)].\(^1\) While DHEA(S)’ precise role remains unclear, DHEA(S) is thought to counteract cortisol’s effects on allostatic load.\(^1\) Specifically, while cortisol has a catabolic function, DHEA(S) seems to have an anabolic, regenerative, and neuroprotective function in the brain and cardiovascular system,\(^1\) which may be mediated through effects on brain derived neurotrophic factor (BDNF) and gamma-aminobutyric-acid (GABA)-metabolism.\(^{70,71}\) Consequently, the cortisol/DHEA(S)-ratio is proposed to represent a balance between catabolic and anabolic activity.\(^{72,73}\)

Although DHEA(S) derived far less attention in MDD compared to cortisol, an elevated cortisol/DHEAS-ratio has been found in MDD-patients and has been proposed as a state marker of MDD.\(^{1,74}\) However, opposite results of no differences or higher DHEA(S) have also been reported.\(^{1,75}\) These conflicting findings may be caused by the relatively small size and large heterogeneity of the investigated samples thus far.\(^1\) Nevertheless, given DHEA(S)’ anabolic effects (e.g. neuroprotection and regeneration), low DHEA(S) - particularly relative to cortisol - could be of clinical importance because it may intensify allostatic load and thereby contribute to recurrence and cardiovascular comorbidity in MDD.\(^{76}\) Therefore, assessment of DHEA(S) in addition to cortisol provides a more complete indication of HPA-axis functioning.

However, the precise characteristics of altered DHEA(S) in MDD remain unknown.\(^1\) Using the sample of the present study, we previously suggested that high cortisol in MDD is a trait (indicating an endophenotype), not a state (epiphenomenon).\(^{69}\) Whether this also holds true for DHEA(S) remains unknown, because of a lack of prospective repeated measures studies.\(^1\) In addition, we observed that cortisol was relatively lower (suggesting HPA-axis blunting/exhaustion) in patients with more previous MDD-episodes (MDEs).\(^{69}\) Other analyses in the recurrent MDD sample showed that cortisol predicted time to recurrence in interaction with cognitive therapy. In detail, while in remitted patients who did not receive cognitive therapy
lower cortisol was associated with early recurrence; in patients who received cognitive therapy higher cortisol levels relatively predicted early recurrence.45,77 Finally, we (based on analyses in the present study’s sample69) and others27 found that psychotherapy resulted in steeper declines in diurnal cortisol. To the best of our knowledge, relations of these factors with DHEA(S) in MDD remain unclear.

Therefore, after examining the above relations in recurrent MDD for cortisol, we aimed to test the following hypotheses for DHEAS and cortisol/DHEAS ratio as well: (I) during remission DHEAS will be lower, and cortisol/DHEAS-ratio higher, than in never-depressed controls (suggesting a trait), (II) DHEAS or cortisol/DHEAS-ratio will not change during the depressive state, (III) more previous MDEs will be associated with lower DHEAS and a higher cortisol/DHEAS-ratio, (IV) higher DHEAS and lower ratio will predict longer time till prospective MDD-recurrence, and (V) psychotherapy will increase DHEAS and decrease the cortisol/DHEAS-ratio.

**METHODS AND MATERIALS**

**Design**
As described previously, for the current study we used a two-staged case-control and prospective-cohort design, that was integrated in a randomized controlled trial assessing recurrence preventing effects of cognitive psychotherapy in recurrent MDD.21,26,69,77 First, in the case-control stage, we obtained saliva samples at study-entry (T0) to cross-sectionally compare patients with controls. Subsequently, we randomized patients to treatment as usual or an additional preventive cognitive therapy (CT)-module. This module consisted of eight weekly group sessions focussing on identification and change of dysfunctional attitudes.26 Treatment as usual consisted of naturalistic care, ranging from continuous antidepressant treatment to no treatment at all. After the 8-week intervention period, we repeated saliva sampling after 3 months (T1) and 2 years (T2) in the patients,69 and performed a 10-year follow-up of clinical symptoms.

**Study sample**
After approval by the ethics committee of the Academic Medical Center of the University of Amsterdam, we recruited 18-65 years old MDD-patients with ≥2 previous MDEs in the last 5 years according to the structural clinical interview for DSM-IV disorder (SCID) which reached remission 10 weeks to 2 years ago, defined as a score ≤9 on the 17-item Hamilton Depression Rating Scale (HDRS).69 We excluded patients with a history of any psychotic, bipolar, or predominant anxiety disorder, organic brain damage, alcohol/drug abuse/dependency, or current steroid use. All subjects gave informed consent. We recruited controls matched for sex and age with no current/past (personal and/or family) axis-I disorders, assessed with the SCID, and no current steroid use.

**Study measures**

*Depression characteristics and covariates*
At T0, we measured educational level (low, middle, and high), anthropometric measures (body mass index, waist and hip circumference), smoking behavior and medication use (including contraceptives) for both patients and controls.
In addition, in patients, we measured current and past MDEs at T0, and at 11 follow-up measurements (at T1, every 3 months until T2, and after 36, 66, and 120 months, i.e. 10 years) using the SCID. In line with previous reports on the present study’s sample,\textsuperscript{26,69} we operationalized previous MDEs dichotomously using a median split (<5 or ≥5 MDEs), because of severe violation of the normality assumption. We address both relapses (<6 months after a previous MDE) and recurrences as ‘recurrence’ for clarity reasons. The trained SCID-evaluators were blind to treatment condition; subjects were instructed not to reveal treatment condition to the interviewers (psychologists/research assistants). We audio-taped all interviews, and two independent experienced psychiatrists - blinded to treatment condition - evaluated all occasions of participants meeting DSM-IV criteria for an MDE. In case of disagreement, psychiatrists’ ratings were used. Kappa for inter-rater agreement between interviewers and psychiatrist on categorization of a relapse/recurrence or no relapse/recurrence was .96, indicating high agreement.\textsuperscript{26,69}

**Hormone measures**

In the saliva samples obtained at T0 in both patients and controls, and additionally at T1 and T2 in patients, we measured cortisol and DHEAS. At each of these three time points, we collected three saliva samples using neutral cotton salivettes (Sarstedt\textsuperscript{TM}): day 1 at 0800 h, day 1 at 2200 h, and day 2 at 0800 h. Salivettes provide a relatively stress free way to obtain hormone measures; they are also applicable for DHEAS.\textsuperscript{78} As described previously in our report on the cortisol measures of the present study’s sample,\textsuperscript{69} we instructed participants not to eat overnight, not to brush their teeth and rinse their mouth with water immediately before collecting their saliva, to keep their samples refrigerated, and to send them back by mail on the second day. After receipt, we stored samples at −20 °C until radioimmunoassay analysis (IBL, Hamburg; designed for saliva samples). Intra- and interassay variations were 5.1% and 6.5% for cortisol, and 7.3 and 7.9% for DHEAS, respectively.

**Data analysis**

**Data cleaning and multiple imputation**

We considered measures exceeding >4 standard deviations from the mean as missing, because of suggestive blood contamination.\textsuperscript{69} To reduce bias potentially introduced by missing values, we applied multiple imputation using Amelia II to obtain less biased effects estimates.\textsuperscript{46,69} We used five separate imputed data sets for both our study designs (i.e. cross-sectional and longitudinal prospective cohort-study).\textsuperscript{69} After imputation, we tested whether the day-to-day variability in the two subsequent morning DHEAS measurements was comparable between patients and controls, so we could take the average. The within-subject coefficient of variation for the two subsequent morning T0 measurements was 31.67%, and did not differ between patients and controls (\(P = .480\)).\textsuperscript{79} Therefore, we calculated mean DHEAS over the 2-day morning measurements at T0, T1, and T2. In addition, we calculated the molar cortisol/DHEAS-ratio by dividing cortisol by DHEAS molar concentrations. We used natural log transformations to obtain normal distributions. To get pooled test results from the imputed data sets, we used an SPSS-macro.\textsuperscript{69}

**Subject characteristics and propensity scores**

We compared baseline characteristics of patients and controls using \(\chi^2\) and Student’s independent t-test statistics. We used a propensity score to adjust for multiple potential confounders without losing too much statistical power. We calculated a propensity
score (PS1) for the cross-sectional analyses in patients and controls, based on sex, age, educational level, contraceptive use, last month steroid use, smoking, weight and waist and hip circumference. For the longitudinal analyses (except for the effect of randomized CT) in patients we calculated another propensity score (PS2) additionally including alcohol and drug use during follow-up (yes/no), benzodiazepine use (yes/no), treatment with CT (yes/no) and continuous use of antidepressants (yes/no).

Statistical analyses
We used SPSS Statistics 20.0 (IBM Corp., 2011) for all statistical analyses. In accordance with our previous report on cortisol measures from the present study’s sample, we tested hypotheses I-III and V using marginal linear regression models with unstructured covariance matrices with DHEAS or cortisol/DHEAS-ratio as the dependent variable. For hypothesis I, independent variables were sampling moment (morning/evening), group (patient/control) and the moment × group-interaction. For the subsequent hypotheses, independent variables were follow-up time (T0/T1/T2), sampling moment (morning/evening) and the appropriate covariate for each research question, i.e. depressive state as a time-dependent factor at T0, T1 and T2 (yes/no) for hypothesis II; previous MDEs determined at T0 (<5 or ≥5 MDEs) for hypothesis III; and CT (yes/no) for hypothesis V, including relevant interactions. When higher order interactions were not significant we removed them from the model and used the most parsimonious model. For our fourth hypothesis (do T0 hormone concentrations predict time until recurrence?) we used a Cox proportional hazard model. Because we previously showed an interaction between previous MDEs and CT, we used DHEAS or cortisol/DHEAS-ratio, treatment condition (treatment as usual versus CT), previous MDEs (≥5 versus <5) and their interactions as predictors, and time till the start of the first recurrence or end of observation during the 10-year follow-up in days as right censored dependent variable. As Cox-models cannot combine these, we used separate Cox models for morning and evening measures.

RESULTS

Subject inclusion, characteristics, and missing data (Table 1)
During inclusion, approximately 1000 subjects (31% recruited at psychiatric centers; 69% through media announcements) were telephonically screened, 321 were interviewed, resulting in 187 included patients. In addition, 72 matched controls were included. Of the patients, 15 dropped out of the study’s CT, but HPA-axis data was collected so they were included in all analyses. Drop-outs were younger than completers, but did not differ on other characteristics (P > .05). For the 172 remaining patients 10.7%, 21.7% and 42.6% of the hormone measures was missing at T0, T1 and T2 respectively. For the 72 controls 10.6% was missing at T0. In total 1361 measures were obtained at T0, T1 and T2, from which seven were assigned missing due to probable blood contamination.

Patients and controls were successfully matched on sex and age; however, patients had a lower educational level, higher weight and larger waist circumference (Table 1). Patients had a mean of 6.3 previous MDEs. During the 10-years follow-up an estimated 82.4% (154/187) experienced a recurrence.
Hypothesis I: differences between remitted MDD-patients and controls (Figure 1)
The diurnal course of DHEAS over the day showed a significantly steeper decline in patients than in controls (group × moment interaction; $P = .001$). These effects remained after adjustment for potential confounders using PSA. Post hoc tests comparing morning and evening values separately, showed that morning DHEAS did not differ, while evening DHEAS was significantly lower in patients compared to controls ($P = .001$).

For the cortisol/DHEAS-ratio, the patients showed a flatter diurnal profile than controls (group × moment interaction; $P < .001$), which remained after correction for confounders. Post hoc tests showed no differences in the morning, but a significantly higher ratio for patients compared to controls in the evening ($P < .001$).

Hypothesis II: changes during an MDE (Figure 2)
In patients, DHEAS and cortisol/DHEAS-ratio were not associated with the state of being depressed (yes/no) during follow-up according to the SCID at the given sampling time-points (T0/T1/T2) (state-effect; $P = .566$, $P = .330$, respectively), also not after omitting the equally non-significant effect of course over the day (state × moment-interaction; $P = .941$, $P = .617$, respectively).

Table 1. Subject characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients ($N = 187$)</th>
<th>Controls ($N = 72$)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female %</td>
<td>68.1</td>
<td>72.7</td>
<td>.456</td>
</tr>
<tr>
<td>Age, mean (SD), year</td>
<td>44.2 (9.7)</td>
<td>44.9 (9.3)</td>
<td>.61</td>
</tr>
<tr>
<td>Educational level</td>
<td></td>
<td></td>
<td>$&lt; .001$</td>
</tr>
<tr>
<td>Low, %</td>
<td>33.2</td>
<td>4.6</td>
<td></td>
</tr>
<tr>
<td>Middle, %</td>
<td>32.6</td>
<td>19.7</td>
<td></td>
</tr>
<tr>
<td>High, %</td>
<td>34.2</td>
<td>72.3</td>
<td></td>
</tr>
<tr>
<td>Smoking, %</td>
<td>29.9</td>
<td>22.9</td>
<td>.28</td>
</tr>
<tr>
<td>Weight, mean (SD), cm</td>
<td>78.9 (16.3)</td>
<td>73.76 (13.4)</td>
<td>.04</td>
</tr>
<tr>
<td>Waist circumference, mean (SD), cm</td>
<td>89.3 (13.9)</td>
<td>83.7 (12.3)</td>
<td>.01</td>
</tr>
<tr>
<td>Hip circumference, mean (SD), cm</td>
<td>105.3 (11.1)</td>
<td>103.1 (7.8)</td>
<td>.13</td>
</tr>
<tr>
<td>Oral contraceptive use, %</td>
<td>22.1</td>
<td>17.1</td>
<td>.40</td>
</tr>
<tr>
<td>Steroid use in month before assessment, %</td>
<td>.6</td>
<td>1.4</td>
<td>.57</td>
</tr>
<tr>
<td>Benzodiazepine use, %</td>
<td>8.0</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Continuous AD use during follow-up, %</td>
<td>27.3</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Antidepressant use at study entry, %</td>
<td>42.2</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>TCA, %</td>
<td>3.9</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>SSRI, %</td>
<td>29.2</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Other, %</td>
<td>9.1</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Received cognitive therapy, %</td>
<td>51.9</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>HDRS, score, mean (SD)</td>
<td>3.8 (2.9)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Number of previous episodes, mean (SD)</td>
<td>6.3 (8.1)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Five or more previous episodes, %</td>
<td>40.6</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Age of onset first episode, mean (SD), year</td>
<td>28.5 (12.5)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Depressed at T1, %</td>
<td>15.0</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Depressed at T2, %</td>
<td>16.0</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AD, antidepressant; HDRS, Hamilton depression rating scale; SSRI, selective serotonin reuptake inhibitor; T0, study-entry; T1, T2, 3 months and 2 years of follow-up respectively; TCA, tricyclic antidepressant.
Figure 1. DHEAS concentrations and cortisol/DHEAS-ratio for recurrent MDD-patients in remission ($N = 187$) compared to controls ($N = 72$). Compared to matched controls, patients showed a steeper decline in DHEAS’ diurnal course over the day and a flatter diurnal profile of molar cortisol/DHEAS ratio. Marginal linear regression model analyses results; remitted patients versus controls group × moment interaction $F_{1,441.59} = 11.26$, $P = .001$; $F_{1,98,33} = 20.24$, $P < .001$, for DHEAS and ratio, respectively. Results were adjusted for sex, age, educational level, contraceptive and steroid use, smoking, weight and waist and hip circumference. Error bars indicate SE, *** indicates $P \leq .001$.

Figure 2. DHEAS concentrations and cortisol/DHEAS-ratio for patients that had a current depressive episode compared to patients that did not experience a recurrence during sampling moment T1 (after 3 months) and T2 (after 2 years of follow up). Both DHEAS and molar cortisol/DHEAS ratio showed no changes during a follow-up recurrence. Marginal linear regression model analyses results for DHEAS and cortisol/DHEAS-ratio $F_{1,30.18} = .34$, $P = .566$; $F_{1,28.13} = .981$, $P = .330$, respectively. Error bars indicate SE. Measures obtained at study entry (T0) were not included in the figure because all MDD patients were in remission at T0 as according to the inclusion criteria. These measurements were included in the analysis though.
Hypothesis III: association with previous MDEs (Supplemental Figure 1)
There were no significant differences between patients with ≥5 previous MDEs compared to patients with <5 previous MDEs for DHEAS and cortisol/DHEAS-ratio (previous MDEs-effect, \( P = .743 \) and \( P = .803 \), respectively), their courses over the day (MDEs × moment-interaction; \( P = .686 \) and \( P = .569 \)) and follow-up (MDEs × follow-up-interaction; \( P = .527 \) and \( P = .617 \)). Adjustment for confounders did not change these findings.

Supplemental Figure 1 related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.psyneuen.2015.05.006.

Hypothesis IV: association with recurrence (Figure 3)
The analysis of the predictive effect of study-entry (T0) hormone concentrations on prospective time until recurrence over the 10-year follow-up revealed a significant three-way interaction between morning cortisol/DHEAS-ratio, previous MDEs and treatment condition (CT versus treatment as usual; Wald statistic\( _{1,187}^{N} = 5.08 \), \( P = .026 \), hazard ratio = .48, 95% CI = 0.25-0.92). The evening cortisol/DHEAS-ratio showed a similar trend (Wald statistic\( _{1,187}^{N} = 2.88 \), \( P = .091 \), hazard ratio = .60, 95% CI = 0.33-1.09), in line with an opposite trend for morning DHEAS itself (Wald statistic\( _{1,187}^{N} = 3.22 \), \( P = .073 \), hazard ratio = 1.83, 95% CI = 0.94-3.55). The three-way interaction for evening DHEAS also showed an opposite but non-significant effect (Wald statistic\( _{1,187}^{N} = 2.21 \), \( P = .138 \), hazard ratio = 1.57, 95% CI = 0.87-2.86). Lower order interactions and main effects were not significant.

Post hoc tests for the significant three-way interaction of the morning cortisol/DHEAS-ratio showed that it was driven by a two-way interaction of cortisol/DHEAS-ratio and CT in patients who had experienced <5 previous MDEs. More specifically: in patients with <5 previous MDEs, cortisol/DHEAS-ratio (dichotomized for graphical purposes, using median split) showed a significant two-way interaction with CT (Wald statistic\( _{1,111}^{N} = 5.48 \), \( P = .021 \), hazard ratio = .32, 95% CI = 0.12-0.84). In patients with <5 MDEs who were randomized to CT a higher ratio was associated with shorter time until recurrence, while in patients with <5 MDEs who were randomized to treatment as usual a higher ratio was associated with longer time till recurrence. This two-way interaction was not present in patients with ≥5 MDEs (\( P = .686 \)).

Hypothesis V: effect of CT (Supplemental Figure 2)
After eight weeks of CT, DHEAS and cortisol/DHEAS-ratio during follow-up at T1 and T2 of patients who received CT were compared with patients who had not received CT. Three-way, two-way and main effects of CT were not significant, indicating that CT had no overall effect on DHEAS or cortisol/DHEAS-ratio, nor their courses over the day or follow-up.

Supplemental Figure 2 related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.psyneuen.2015.05.006.
DISCUSSION

The present study first cross-sectionally compared remitted MDD-patients with matched controls, and showed a steeper DHEAS-decline over the day and a flatter diurnal profile of cortisol/DHEAS-ratio in patients compared to controls. Particularly evening values were altered, with lower DHEAS and higher ratios in patients. Repeated measures during follow-up of patients showed no changes in DHEAS and cortisol/DHEAS-ratio during new MDEs. Furthermore, higher study-entry morning cortisol/DHEAS-ratios relatively predicted sooner recurrence during 10-years follow-up in patients that were randomized to CT and experienced <5 previous MDEs. Finally, CT did not influence DHEAS and cortisol/DHEAS-ratio.

Hypothesis I and II: steeper diurnal DHEAS decline and flatter diurnal profile of cortisol/DHEAS-ratio as a trait, not a state

Directions of alterations

Our results show that the direction of alterations depends on time of the day: DHEAS had a steeper decline over the day, while the cortisol/DHEAS-ratio diurnal profile was flatter compared to controls. Differences were most pronounced in the evening, i.e. lower DHEAS and higher ratio. This fits with the general findings in previous literature in MDD,1 and with findings of higher cortisol in the present study’s sample.69 However, contradictory findings exist.75,80 This heterogeneity may be explained by several factors, including patient characteristics (age, MDD-subpopulation, medication use), methodological factors (stress-
free salivary versus blood samples, sampling time, small sample sizes), or theoretical aspects (DHEA versus DHEAS-measurements, using ratio over cortisol). Our study provides additional knowledge, by using repeated measures to show stable steeper diurnal DHEAS declines and flatter diurnal cortisol/DHEAS-ratio profiles in saliva in a specific but large group of recurrent MDD-patients compared to carefully matched controls. This again stresses the importance of diurnal timing of measurements, and the difference of using DHEAS versus its cortisol-ratio, which may guide future studies aimed at corroborating these findings to further unravel the precise role of DHEA(S) in MDD.

**Trait versus State**

In accordance with our hypotheses, our longitudinal results show that the HPA-axis alterations do not change during an MDE, which suggests a trait nature. This is in line with results for only cortisol in the present study sample. Moreover, these findings correspond with earlier cross-sectional studies observing persistent DHEAS-alterations in a small sample of remitted MDD-patients, and a state-independent trait of DHEAS-alterations in schizophrenia. However, it may seem inconsistent with cross-sectional studies showing DHEA(S)-differences in remitted compared to depressed MDD-subjects and associations between DHEAS and MDD-symptom severity. Moreover, previous studies showed associations between DHEA(S)-reductions and remission during antidepressant treatment. However, other studies suggested that these associations between DHEA(S) and remission already exist before treatment or even before MDD-onset.

In sum, a seemingly inconsistent picture arises: MDD-patients exhibit DHEA(S)-alterations, that seem to be equally present before the first MDE and in between subsequent MDEs (i.e. trait instead of state) (present data and Girdler et al., 2012). On the other hand, DHEA(S) is cross-sectionally associated with MDD-symptom severity and successful treatment with antidepressants. This seems to be similar to what have been demonstrated for cortisol, several explanations for these apparent inconsistencies could be thought of.

The associations between DHEAS and symptom severity reported in previous cross-sectional studies could be compatible with a trait when they actually reflect an indirect effect instead of a direct state-effect. For instance, patients who are most vulnerable to MDD could exhibit both a more outspoken trait of DHEAS-alterations and more MDD-symptoms at a given cross-sectional measurement point. Thereby, this indirect effect - next to other possible confounding factors - may explain the previously observed cross-sectional associations. We now present the current, to the best of our knowledge first, long-term longitudinal study, which enables us to disentangle these direct and indirect effects using a within-subject repeated measures design. This approach suggests that there are no changes in DHEAS when a remitted patient enters a new MDE.

Regarding the association between DHEA(S) and successful antidepressant treatment, it may be that the DHEA(S)-reductions do not reflect symptom change (i.e. a state effect), but are rather a proxy for (the possibility of) successful treatment. For example, as noted before, antidepressants’ effect on multidrug resistance p-glycoprotein may be a prerequisite for their clinical effectiveness. Given that DHEAS also is a substrate for p-glycoprotein, the changes in DHEAS during successful antidepressant treatment may not reflect a state-effect, but rather the effective modulation of p-glycoprotein by the antidepressant.
Altogether, previous literature and the current study’s data suggest that similar to findings for cortisol in the present study’s sample, DHEAS-alterations form part of an endophenotypic HPA-axis trait in recurrent MDD. However, inconsistencies regarding the direction of alterations and changes during antidepressant treatment still preclude firm conclusions. Also given that the present study is the first long-term longitudinal repeated measures study of DHEAS in MDD, it is important to confirm results in future studies.

**Hypothesis III: no association with previous MDEs**
In contrast to our third hypothesis, we found no associations of DHEAS(-ratio) with number of previous MDEs. This suggests that there are no exhaustion or scarring effects of previous MDEs on DHEAS. This contrasts findings in present study’s sample showing that cortisol alone was present in lower concentrations in patients with more previous episodes. This could also be interpreted as support for the notion that DHEAS-alterations might reflect a relatively stable endophenotype in recurrent MDD.

**Hypothesis IV: predictive effect on time till recurrence**
Our 10-year follow-up provided the opportunity to test predictive effects of DHEAS and cortisol/DHEAS-ratio on time till recurrence. Moreover, because the study was integrated in a randomized controlled trial, we could test interaction-effects with recurrence-preventing CT as we previously did for cortisol in the present study’s sample. Interestingly, we observed an interaction between morning cortisol/DHEAS-ratio and treatment in patients with <5 previous MDEs. Of note, the direction was as expected in patients randomized to CT (higher ratio predicted detrimental clinical course), but opposite in the treatment as usual group. Given the lack of previous studies investigating these predictive relations, interpretation remains somewhat speculative. The unexpected finding that low cortisol/DHEAS-ratio was associated with shorter time till recurrence in the treatment as usual group may correspond with earlier findings in the present study’s sample showing that higher cortisol protected against recurrence over 5.5 years in the patients that did not receive CT (treatment as usual group). The effect was in the expected direction in the CT-group: low cortisol/DHEAS-ratio was associated with longer time till recurrence. This could be caused by enhancing effects of DHEAS on memory and cognition, which make patients with a relatively lower cortisol/DHEAS-ratio more receptive for CT’s recurrence preventing effects. Analogically, lower cortisol (and higher DHEAS) prospectively predicted post-traumatic stress disorder (PTSD)-symptoms in trauma center patients.

**Hypothesis V: no effects of CT**
Contrary to our hypotheses, our intention to treat analysis showed no effects of randomized CT on DHEAS or cortisol/DHEAS-ratio. This differs from findings (also in the present study’s sample) showing that CT can influence cortisol in MDD and PTSD. Nevertheless, this lack of effect of CT on DHEAS again contributes to the view of DHEAS-alterations as an endophenotype in MDD. In addition, it suggests that if CT’s effects in MDD are (partly) mediated through the HPA-axis, they are not general but selective for cortisol.
Strengths and limitations

Some limitations should be noted. First, we did not obtain information on awakening time nor multiple consecutive morning saliva samples on the same day. Although it remains uncertain whether DHEAS shows an awakening response like cortisol, we consequently could not include this possible awakening response in our models.

Second, we did not include detailed lifestyle variables in our model, e.g. physical activity, employment status, sleep pattern, and weekday versus weekend sampling. However, we did correct for e.g. alcohol/drug use, smoking, weight, and waist/hip circumference, which are known to be associated with other lifestyle variables. Possible consequences of these two shortcomings may be twofold, on the one hand they could have induced differences that do not directly reflect MDD’s pathophysiology, e.g. when patients handled sampling protocols differently. On the other hand, these variables could have increased external variability thereby decreasing the ability to detect differences. Nonetheless, we observed consistent and relevant effects, systematically using identical methodology in patients and controls.

Third, we did not distinguish between different MDD-subtypes, for which the cortisol/DHEAS-ratio may be an interesting addition in future research given the observed cortisol differences between e.g. melancholic and atypical MDD. In addition, in order to specify the endophenotype, it may be interesting to investigate the association of DHEAS with a specific symptom of the depressive spectrum [e.g. libido loss, considering DHEA(S)’ androgenic effects] instead of the whole heterogeneity of symptoms.

Fourth, the present study was a naturalistic study, which implies that antidepressant use was no exclusion criterion. However, we observed no effect of antidepressant use in patients (continuous use yes/no) on cortisol or DHEAS in post hoc tests (P’s > .554), and corrected for antidepressant use in the longitudinal analyses.

Fifth, we did not include measures of stress or psychological trauma in our models. However, post hoc analyses showed no association of DHEAS with childhood life event- or daily hassle-questionnaire-scores, neither during follow-up (P’s > .511).

Sixth, DHEAS’ hydrophilic nature may reduce its passage into saliva, which has been suggested to limit the applicability of DHEAS as a salivary biomarker. However, evidence shows that (I) correlations between serum and saliva DHEAS-concentrations are comparable to those for cortisol, also after stress, and (II) salivettes and passive drool collection methods can be used interchangeably. Finally, we did not additionally measure DHEA. Although DHEAS can be converted into DHEA and vice versa, it would have been interesting to also measure DHEA to improve comparability with previous literature specifically on DHEA.

Our study also had its strengths, especially our exclusive study sample and unique design. We included a large, relatively homogeneous, sample of patients with highly recurrent MDD. In addition, combining cross-sectional patient-control comparisons with repeated saliva samples over a long-term period, allowed us to specifically assess HPA-axis stability and disentangle trait- and state-effects.

Finally, our very long-term 10-year follow-up enabled to interpret the observed HPA-axis alterations from a long-term clinical perspective.
Relevance and implications for research and clinic

Although the field moved on from the idea of DHEA(S) as a fountain of youth, studies supplementing DHEA(S) for MDD or depressive symptoms suggest some promising effects. However, evidence is limited and long-term risks - including possible carcinogenic effects - potentially limit clinical applicability. Investigation of 7-keto DHEA may be an interesting alternative. However, our results show alterations that differ during the day but seem to remain stable over disease states, suggesting that timing of administration could be important, both diurnally and during disease progression. Next to supplementation, our results suggest that DHEA(S) could also be used as a biomarker to predict clinically relevant events. For example, the observed DHEAS-trait can be part of an allostatic load biomarker panel, which may ultimately serve as a clinical tool to indicate patients that are at increased risk for recurrence and/or cardiovascular disease, guiding the clinician in his preventive treatment. In addition, knowing that patients with a lower cortisol/DHEAS-ratio may be more receptive to CT could help the clinician to better select the optimal recurrence preventing treatment for each individual patient, thereby providing a means to optimize precision/personalized treatment.

CONCLUSION

Results show low evening DHEAS and high evening cortisol/DHEAS-ratio in recurrent MDD, that do not change during an MDE and were not influenced by previous MDEs or CT. This may suggest that, similar to earlier findings for cortisol in the present study’s sample, DHEAS is part of an endophenotypic HPA-axis trait in recurrent MDD. In addition, the fact that the interaction between morning cortisol/DHEAS-ratio and CT-treatment predicted time till recurrence over a 10-year follow-up, may suggest that HPA-axis measures can be used to personalize preventive treatment in recurrent MDD.

ROLE OF THE FUNDING SOURCES

Funding support for this study was provided by the Netherlands Foundation for Mental Health, Utrecht and the Netherlands Organization for Health Research and Development Prevention Program (ZonMw). Both had no further role in study design; the collection, analysis and interpretation of data; the writing of the report; nor the decision to submit the paper for publication.

ACKNOWLEDGEMENTS

We are most grateful to the participants of our study and we express our appreciation to the participating psychiatric sites for their recruitment efforts. We also thank our interviewers and independent raters and specifically Irene Visch for assistance with data management and support. The following colleagues also contributed to the DELTA (Depression Evaluation Longitudinal Therapy Assessment) Study: Mascha ten Doesschate, Jochanan Huyser, Guido Nabarro, Philip Spinhoven, Ellie Wecking and Luuk Wouters.

CONFLICT OF INTEREST

None declared.